<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03361046</url>
  </required_header>
  <id_info>
    <org_study_id>WUM-VIV</org_study_id>
    <nct_id>NCT03361046</nct_id>
  </id_info>
  <brief_title>Polish Transcatheter Aortic Valve-in-Valve Implantation (ViV-TAVI) Registry</brief_title>
  <official_title>Evaluation of Clinical Outcomes of Transcatheter Aortic Valve-in-Valve Implantation in Polish Population - Observational Multicenter Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Warsaw</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Warsaw</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      In the past years a substantial shift away from mechanical heart valves occurred and
      bioprosthetic heart valves claimed majority of market shares irrespective of patients'
      age.This indicates that population with failed surgical bioprostheses requiring ViV-TAVI will
      grow significantly and therefore, meticulous prospective data collection is necessary for
      future analyses in order to better understand potential limitations of this procedure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a prospective multicenter evaluation of transcatheter aortic valve-in-valve
      implantations in Polish health centers.

      Duration of this study is expected to be 6 years to ensure that all of the enrolled patients
      will complete at least 2 years of follow-up.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2018</start_date>
  <completion_date type="Anticipated">May 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>VARC (Valve Academic Research Consortium-2) defined &quot;Clinical Efficacy&quot; composite endpoint</measure>
    <time_frame>From 30 days post procedure to completion of at least 2 years of follow up</time_frame>
    <description>All-cause mortality
All stroke (disabling and non-disabling)
Requiring hospitalizations for valve-related symptoms or worsening congestive heart failure
NYHA (New York Heart Association) class III or IV functional classification of heart failure
Valve-related dysfunction (mean aortic valve gradient ≥20 mmHg, Effective Orifice Area (EOA) ≤0.9-1.1 cm2(c) and/or Doppler Velocity Integral (DVI) &lt;0. 35 m/s, AND/OR moderate or severe prosthetic valve regurgitation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>VARC defined 'Device success' composite endpoint</measure>
    <time_frame>30 days</time_frame>
    <description>Absence of procedural mortality AND
Correct positioning of a single prosthetic heart valve into the proper anatomical location AND
Intended performance of the prosthetic heart valve (no prosthesis - patient mismatch and mean aortic valve gradient ,20 mmHg or peak velocity ,3 m/s, AND no moderate or severe prosthetic valve regurgitation)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VARC defined &quot;Early Safety&quot; composite endpoint</measure>
    <time_frame>30 days</time_frame>
    <description>All-cause mortality
All stroke (disabling and non-disabling)
Life-threatening bleeding
Acute kidney injury—Stage 2 or 3 (including renal replacement therapy)
Coronary artery obstruction requiring intervention
Major vascular complication
Valve-related dysfunction requiring repeat procedure (Balloon Aortic Valvuloplasty (BAV), Trans Catheter Aortic Valve Implant (TAVI), or Surgical Aortic Valve Replacement (SAVR))</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VARC defined &quot;Time-related valve safety&quot; composite endpoint</measure>
    <time_frame>From device implant to completion of at least 2 years of follow up</time_frame>
    <description>Structural valve deterioration
Valve-related dysfunction (mean aortic valve gradient ≥20 mmHg, EOA ≤0.9-1.1 cm2cand/or DVI &lt;0.35 m/s, AND/OR moderate or severe prosthetic valve regurgitation)
Requiring repeat procedure (TAVI or SAVR)
Prosthetic valve endocarditis
Prosthetic valve thrombosis
Thrombo-embolic events (e.g. stroke)
VARC bleeding, unless clearly unrelated to valve therapy (e.g. trauma)</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Aortic Valve Stenosis</condition>
  <condition>Aortic Valve Insufficiency</condition>
  <condition>Ventricular Outflow Obstruction, Left</condition>
  <arm_group>
    <arm_group_label>Transcatheter Aortic Valve-in-Valve Implantation Cohort</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transcatheter Aortic Valve-in-Valve Implantation (ViV-TAVI)</intervention_name>
    <description>Patients with failed aortic valve bioprostheses qualified for TAVI due to coexisting illnesses</description>
    <arm_group_label>Transcatheter Aortic Valve-in-Valve Implantation Cohort</arm_group_label>
    <other_name>Transcatheter Aortic Valve-in-Valve Replacement (ViV-TAVR)</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patients meeting inclusion criteria will prospectively included in the study. Patients
        meeting inclusion criteria before the set-up of registry will be included retrospectively.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Failing surgically implanted aortic bioprosthetic valve (stented/stentless/homograft)
             demonstrating ≥ moderate stenosis and/or ≥ moderate insufficiency

          -  Qualification for TAVI by decision of the local Heart Team

          -  Patient provided written informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zenon Huczek, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Warsaw</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wojciech Wojakowski, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Silesia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kajetan Grodecki</last_name>
    <phone>+48660675782</phone>
    <email>kajetan.grodecki@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Medical University of Bialystok</name>
      <address>
        <city>Białystok</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marek Frank, MD, PhD</last_name>
    </contact>
    <contact_backup>
      <last_name>Paweł Kralisz, MD, PhD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Polish-American Heart Clinic</name>
      <address>
        <city>Bielsko-Biala</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wojciech Fil, MD, PhD</last_name>
    </contact>
    <contact_backup>
      <last_name>Wojciech Domaradzki, MD, PhD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Medical University of Gdansk</name>
      <address>
        <city>Gdańsk</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dariusz Jagielak, MD, PhD</last_name>
    </contact>
    <contact_backup>
      <last_name>Dariusz Ciećwierz, MD, PhD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Medical University of Silesia</name>
      <address>
        <city>Katowice</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wojciech Wojakowski, MD, PhD</last_name>
    </contact>
    <contact_backup>
      <last_name>Radosław Parma, MD, PhD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Jagiellonian University Medical College</name>
      <address>
        <city>Kraków</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dariusz Dudek, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Poznan University of Medical Sciences</name>
      <address>
        <city>Poznań</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marek Grygier, MD, PhD</last_name>
    </contact>
    <contact_backup>
      <last_name>Maciej Lesiak, MD, PhD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>District Hospital 2</name>
      <address>
        <city>Rzeszów</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Piotr Olszówka, MD, PhD</last_name>
    </contact>
    <contact_backup>
      <last_name>Kazimierz Widenka, MD, PhD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Institute of Cardiology</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maciej Dąbrowski, MD, PhD</last_name>
    </contact>
    <contact_backup>
      <last_name>Adam Witkowski, MD, PhD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Medical University of Warsaw</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zenon Huczek, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Kajetan Grodecki</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wroclaw Medical University</name>
      <address>
        <city>Wrocław</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Piotr Kübler, MD, PhD</last_name>
    </contact>
    <contact_backup>
      <last_name>Krzysztof Reczuch, MD, PhD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Silesian Center for Heart Diseases</name>
      <address>
        <city>Zabrze</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Krzysztof Wilczek, MD, PhD</last_name>
    </contact>
    <contact_backup>
      <last_name>Marian Zembala, MD, PhD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Medical University of Lodz</name>
      <address>
        <city>Łódź</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michał Kidawa, MD, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <reference>
    <citation>Kappetein AP, Head SJ, Généreux P, Piazza N, van Mieghem NM, Blackstone EH, Brott TG, Cohen DJ, Cutlip DE, van Es GA, Hahn RT, Kirtane AJ, Krucoff MW, Kodali S, Mack MJ, Mehran R, Rodés-Cabau J, Vranckx P, Webb JG, Windecker S, Serruys PW, Leon MB; Valve Academic Research Consortium (VARC)-2. Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document (VARC-2). Eur J Cardiothorac Surg. 2012 Nov;42(5):S45-60. doi: 10.1093/ejcts/ezs533. Epub 2012 Oct 1.</citation>
    <PMID>23026738</PMID>
  </reference>
  <reference>
    <citation>McElhinney DB, Cabalka AK, Aboulhosn JA, Eicken A, Boudjemline Y, Schubert S, Himbert D, Asnes JD, Salizzoni S, Bocks ML, Cheatham JP, Momenah TS, Kim DW, Schranz D, Meadows J, Thomson JD, Goldstein BH, Crittendon I 3rd, Fagan TE, Webb JG, Horlick E, Delaney JW, Jones TK, Shahanavaz S, Moretti C, Hainstock MR, Kenny DP, Berger F, Rihal CS, Dvir D; Valve-in-Valve International Database (VIVID) Registry. Transcatheter Tricuspid Valve-in-Valve Implantation for the Treatment of Dysfunctional Surgical Bioprosthetic Valves: An International, Multicenter Registry Study. Circulation. 2016 Apr 19;133(16):1582-93. doi: 10.1161/CIRCULATIONAHA.115.019353. Epub 2016 Mar 18.</citation>
    <PMID>26994123</PMID>
  </reference>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 28, 2017</study_first_submitted>
  <study_first_submitted_qc>November 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 4, 2017</study_first_posted>
  <last_update_submitted>March 19, 2018</last_update_submitted>
  <last_update_submitted_qc>March 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TAVI</keyword>
  <keyword>valve-in-valve</keyword>
  <keyword>aortic stenosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
    <mesh_term>Aortic Valve Insufficiency</mesh_term>
    <mesh_term>Ventricular Outflow Obstruction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

